Although no NF-κB inhibitors have been approved to the clinical treatment for MS, the beneficial effects of NF-κB interference by a considerable number of natural components (e.g., piperlongumine and denanthin) have been suggested in basic animal studies (120, 121). The gene discussed is NFKB1; the disease is myeloid sarcoma.